Application of tygecycline separately or in combination with ryphampine for osteomyelitis and/or septic arthritis

FIELD: medicine.

SUBSTANCE: can be used as method of treatment of osteomyelitis and septic arthritis, caused by bacterial agents, including with plural medicinal resistance. For this purpose mammal is introduced with pharmacologically effective amount of tigecycline separately or in combination with ryphampycine antibiotic. This agent is also offered also for manufacturing of medical products for treatment of given diseases.

EFFECT: invention provides increased efficiency of bone, marrow and joints infection treatment to preferential tigecycline distribution through bone tissue, marrow and synovial fluid.

48 cl, 5 dwg, 11 tbl, 3 ex

 

The text descriptions are given in facsimile form.

1. The method of treatment of an infection of bone or bone marrow from a mammal, comprising administration to the mammal a pharmacologically effective is its number of tigecycline.

2. The method according to claim 1, additionally including the introduction of antimicrobial agent selected from the group consisting of rifamycin, rifampin, rifapentine, rifaximin or streptothricin.

3. The method according to claim 2, where the antimicrobial agent is a rifampin.

4. The method according to claims 1, 2 or 3, where infection caused by a pathogen selected from the group consisting of gram-negative bacteria, gram-positive bacteria, anaerobic bacteria and aerobic bacteria.

5. The method according to claim 4, where the pathogen is selected from the group consisting of Staphylococcus, Acinetobacter, Mycobacterium, Haemophilus, Salmonella, Streptococcus, Enterobacteriaceae, Enterococcus, Escherichia, Pseudomonas, Neisseria, Rickettsia, Pneumococci, Prevotella, Peptostreptococci, Bacteroides, Legionella spp., beta-hemolytic Streptococcus, group b Streptococcus and Spirochaetes.

6. The method according to claim 5, where the infection includes infection caused by Neisseria, Mycobacterium, Staphylococcus and Haemophilus.

7. The method according to claim 6, where the infection includes infection caused by Neisseria meningitidis, Mycobacterium tuberculosis, Mycobacterium leprae, Staphylococcus aureus, Staphylococcus epidermidis, or Haemophilus influenzae.

8. The method according to claim 4, where the pathogen is resistant to antibiotics.

9. The method of claim 8, where the resistance to antibiotics is selected from the group consisting of resistance to methicillin, resistance to glycopeptides, resistance to tetracycline, resistance to oxytetracycline, resistance to doxycycline, resistance to chlortetracycline, resistance to minoti the Lin, resistance to glycylcyclines, resistance to cephalosporins, resistance to ciprofloxacin, resistance to nitrofurantoin, resistance to trimethoprim-sulfa, resistance to piperacillin/tazobactam, resistance to moxifloxacin, resistance to vancomycin resistance teicoplanin, resistance to penicillin and resistance to macrolides.

10. The method according to claim 9, where the resistance to glycopeptides is a resistance to vancomycin.

11. The method according to claim 5, where the pathogen is selected from the group consisting of Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pneumoniae, or Streptococcus pyogenes.

12. The method according to claim 11, where the infection is caused by Staphylococcus aureus.

13. The method according to item 12, where Staphylococcus aureus resistant, selected from the group consisting of resistance to glycopeptides, resistance to tetracycline, resistance to minocycline, resistance to methicillin, resistance to vancomycin and resistance to glycylcyclines the antibiotics different from tigecycline.

14. The method according to claim 5, where the infection includes infection with Acinetobacter baumannii.

15. The method according to 14, where Acinetobacter baumannii resistant to antibiotics selected from the group consisting of resistance to cephalosporins, resistance to ciprofloxacin, resistance to nitrofurantoin, resistance to trimethoprim-sulfa and resistance to piperacillin/tazobactam.

16. Pic is b according to claim 5, where infection includes infection of Mycobacterium abscessus.

17. The method according to clause 16, where Mycobacterium abscessus resistant to moxifloxacin.

18. The method according to claim 5, where the infection includes infection Haemophilus influenzae.

19. The method according to claim 5, where the infection includes infection Enterococcus faecium.

20. The method according to claim 5, where the infection includes infection of Escherichia coli.

21. The method according to claim 5, where the infection includes infection with Neisseria gonorrhoeae.

22. The method according to claim 5, where the infection includes infection with Rickettsia prowazekii, Rickettsia typhi or Rickettsia rickettsii.

23. The method according to claim 4, where the infection causes osteomyelitis.

24. A method of treating infection of the joint or infection of the surrounding tissues of the joint, which are bone or joint tissue, or joint fluid of a mammal, comprising administration to the mammal a pharmacologically effective amount of tigecycline.

25. The method according to paragraph 24, further including the introduction of antimicrobial agent selected from the group consisting of rifamycin, rifampin, rifapentine, rifaximin or streptothricin.

26. The method according A.25, where the antimicrobial agent is a rifampin.

27. The method according to PP, 25 or 26, where the infection caused by a pathogen selected from the group consisting of gram-negative bacteria, gram-positive bacteria, anaerobic bacteria and aerobic bacteria.

28. The method according to item 27, where the pathogen is selected from the group sotoyama is from Staphylococcus, Acinetobacter, Mycobacterium, Haemophilus, Salmonella, Streptococcus, Enterobacteriaceae, Enterococcus, Escherichia, Pseudomonas, Neisseria, Rickettsia, Pneumococci, Prevotella, Peptostreptococci, Bacteroides, Legionella spp., beta-hemolytic Streptococcus, group b Streptococcus and Spirochaetes.

29. The method according to p, where infection includes infection caused by Neisseria, Mycobacterium, Staphylococcus and Haemophilus.

30. The method according to clause 29, where the infection includes infection caused by Neisseria meningitidis, Mycobacterium tuberculosis, Mycobacterium leprae, Staphylococcus aureus, Staphylococcus epidermidis, or Haemophilus influenzae.

31. The method according to item 27, where the pathogen is resistant to antibiotics.

32. The method according to p, where resistance to antibiotics selected from the group consisting of resistance to methicillin, resistance to glycopeptides, resistance to tetracycline, resistance to oxytetracycline, resistance to doxycycline, resistance to chlortetracycline, resistance to minocycline, resistance to glycylcyclines, resistance to cephalosporins, resistance to ciprofloxacin, resistance to nitrofurantoin, resistance to trimethoprim-sulfa, resistance to piperacillin/tazobactam, resistance to moxifloxacin, resistance to vancomycin resistance teicoplanin, resistance to penicillin and resistance to macrolides.

33. The method according to p, where resistance to glycopeptides is a resistance to vancomycin.

34. The method according to p, where the pathogen is selected from the group SOS is oasa of Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pneumoniae, or Streptococcus pyogenes.

35. The method according to clause 34, where the infection is caused by Staphylococcus aureus.

36. The method according to p, where Staphylococcus aureus resistant, selected from the group consisting of resistance to glycopeptides, resistance to tetracycline, resistance to minocycline, resistance to methicillin, resistance to vancomycin and resistance to glycylcyclines the antibiotics different from tigecycline.

37. The method according to p, where infection includes infection with Acinetobacter baumannii.

38. The method according to clause 37, where Acinetobacter baumannii resistant to antibiotics selected from the group consisting of resistance to cephalosporins, resistance to ciprofloxacin, resistance to nitrofurantoin, resistance to trimethoprim-sulfa and resistance to piperacillin/tazobactam.

39. The method according to p, where infection includes infection of Mycobacterium abscessus.

40. The method according to 39, where Mycobacterium abscessus resistant to moxifloxacin.

41. The method according to p, where infection comprises an infection by a pathogen selected from the group consisting of Haemophilus influenzae, Enterococcus faecium, Escherichia coli, Neisseria gonorrhoeae, Rickettsia prowazekii, Rickettsia typhi or Rickettsia rickettsii.

42. The method according to item 27, where the infection of the joint or infection of the surrounding tissues of the joint cause septic arthritis.

43. The application of a pharmacologically effective amount of tigecycline to treat infections of the bone, to the spas of the brain or joints in a mammal.

44. The application of a pharmacologically effective amount of tigecycline and antimicrobial agent selected from the group consisting of rifamycin, rifampin, rifapentine, rifaximin or streptothricin, to treat infections of the bone, bone marrow, or the joints of a mammal.

45. The application of a pharmacologically effective amount of tigecycline for the manufacture of a medicinal product for the treatment of bone infections, bone marrow or joints in a mammal.

46. The application of a pharmacologically effective amount of tigecycline and antimicrobial agent selected from the group consisting of rifamycin, rifampin, rifapentine, rifaximin or streptothricin for the manufacture of a medicinal product for the treatment of bone infections, bone marrow or joints in a mammal.

47. Use PP-45, where infection of bone or bone marrow causes osteomyelitis.

48. Use PP-45, where the infection of the joint or infection of the tissues surrounding the joint, causing septic arthritis.



 

Same patents:

FIELD: chemistry.

SUBSTANCE: invention relates to the N" -substituted 9a-N-(N'- carbamoyl-γ-aminopropyl) and 9a-M-(M'-thiocarbamoyl-γ-aminopropyl)) derivatives of 9-desoxo-9-dihydro-9a-ase-9a-homoerythromycine A or 5-O-desosaminyl-9-desoxo-9-dihydro-9a-ase-9a-homoerythronolide A, novel semisynthetic macrolide antibiotics from the group of azalides with the common formula 1, where R means H or cladinosyl fragment, R means H, R means the isopropyl group, 1-naphtyl, 2-naphtyl, benzene, 2-(trifluoromethyl)phenyl, 3-phenylpropyl, (3-phenylethyl, ehtoxicarbonylmethyl, 1-(1-naphtyl)ethyl, 3,4,5-trimethoxiphenyl and 2,4-dichlorphenyl, and X means O or S, or to their pharmaceutically compliant additive salts with the inorganic or organic acids and to the method of their production. The invention also relates to the pharmaceutical composition with the antibacterial activity and to the application of the compounds with the common formula 1 or their pharmaceutically compliant salts, in producing the said composition.

EFFECT: antibacterial activity.

16 cl, 26 ex, 1 tbl

FIELD: medicine; pharmacology.

SUBSTANCE: ointment includes vegetable raw materials: sprouts and buds of poplar, aspen or willow, swallowwort (herb and blossom), common wormwood herb, yellow melilot (herb and blossom), costmary (herb and blossom), silver fir (sprouts), Siberian cedar (sprouts), pine resin and fat base, vegetable raw materials ratio is 1:10. As fat base composition contains unsalted pork fat.

EFFECT: extended range of preventive and therapeutic vegetable-based medicinal agents providing effective treatment of inflammatory diseases.

2 cl, 3 ex

FIELD: medicine; veterinary science.

SUBSTANCE: medicinal agent is spirit tincture made on basis of mixed Scotch pine buds, purple Echinacea herb and blossom clusters, horseheal rhizomes and roots, taken in proportion 2:1:1 with 70% concentrated ethyl alcohol 70% at raw and extractant ratio 1:5. Spirit tincture is exposed within 7 days in dark place at temperature 18-20°C. Calves ate treated within three courses every 48 hours with medicinal agent as 3.5-5.0% aqueous solution taken 2.0-3.0 ml/m3 during 45-60 minutes.

EFFECT: provided immunocorrection of key immunity disorders and increased natural resistivity of calves.

2 cl, 4 tbl, 6 ex

FIELD: medicine; pharmacology.

SUBSTANCE: invention is medicinal agent containing rybafutin, copolymer of lactic and glycolic acids (PLGA 50/50), D-mannitol, polysorbate 80 and dimethyl sulfoxide, as well as related method of production implying that mixed rybafutin, PLGA 50/50, D- mannitol, polysorbate 80 are heated at 50÷60°C and stirred until solid phase is completely dissolved, then cooled to room temperature, added with water at ratio 1 : 20 to 1 : 10 followed with nanoparticles˜200÷400 nm suspension produced as a result.

EFFECT: reduced toxicity of active substance accompanying maintained antimicrobic action and simplified production of end formulation.

3 cl, 4 ex, 4 tbl, 1 dwg

FIELD: medicine; pharmacology.

SUBSTANCE: agent contains antibacterial substance of fluoroquinolones, hydrophilic base and optionally at least one adjuvant. As hydrophilic base agent contains silicone glycerohydrogel of composition Si(C3H7O3)4 · xC3H8O3 · yH2O, where 3 ≤ x ≤ 10, 20 ≤ y ≤40. As antibacterial substance of fluoroquinolones agent contains perphloxacyn, ophloxacyn, cyprophloxacyn, norphloxacyn, lomephloxacyn, moxyphloxacyn, csparphloxacyn or enoxacyn. Agent can contain as adjuvant chlorhexidine bigluconate, lydocaine hydrochloride, sea-buckthorn oil, brier oil or mixture. New agent for treatment of suppurative-inflammatory skin and soft tissues diseases including decubitus ulcers, burns, trophic ulcer, has high antibacterial effect due to wide antibacterial action (fluoroquinolones) and high transcutaneous and anti-edematous activity (silicone glycerohydrogel), and do not carry negative by-effects.

EFFECT: agent is stable, easy for keeping and well wipe-off.

6 cl, 5 dwg, 3 tbl, 6 ex

FIELD: medicine; pharmaceutics.

SUBSTANCE: pharmaceutical formulations contains as reactants 1) betamethasone dipropionate or 2) betamethasone dipropionate combined with gentamicin sulphate or 3) betamethasone dipropionate combined with gentamicin sulphate and clotrimazole. Pharmaceutical formulations contain ointment hydrophobic base containing white petrolatum and target additives - preserving agent and hydrophobic nonaqueous solvent. New pharmaceutical formulations have high antibacterial preserving action, high microbiological purity value and potentised antibacterial specific action showed by produced therapeutic effect and simultaneous prevention of by-effect local complication caused by activation of bacterial and mycotic infections.

EFFECT: prevention of by-effect local complication caused by activation of bacterial and mycotic infections.

18 cl, 11 tbl, 6 ex

FIELD: technological processes.

SUBSTANCE: protein variants are suggested that possess lysozyme activity. Protein-based antibacterial substance is described. DNA molecule is discovered that codes the specified protein, and also procariotic cell is discovered that contained the specified DNA molecule. Method is described to prepare protein with the help of procariotic cell.

EFFECT: simplifies preparation of antibacterial substance in commercially significant volumes.

13 cl, 3 ex

FIELD: chemistry.

SUBSTANCE: invention relates to new derivatives of N-form hydroxylamine of the formula (I) where X means -CH2-, -CH(OH)-, -CH(OR)-,-CF2- or -CH(F) - where R meansC1-C7alkyl, R1 means phenyl, quinoline, izo quinoline, pyridyl oxypyridyl, unessentially replaced by substitutesR6, R7, R8, R9, or means a structural fragment of the formula where each of R10 and R11 independently means H, halogen; everyoneR2, R3, R4, R5 independently means H, C1-C7alkyl, n is equal to 0-2 provided that if n is equal to 0 Xmeans-CH2 everyone of R6, R7, R8, R9 H, OH independently means, halogen, C1-C7alkyl, replaced by halogen C1-C7alkyl, C1-C7alkoxy, phenyl or its pharmaceutically acceptable salt.

EFFECT: compounds display high anti-bacteria activity.

12 cl, 1 tbl, 50 ex

FIELD: medicine; chemical and pharmaceutical industry.

SUBSTANCE: gel contains, mass %: active substance - enterosgel - 10.0, preservative agent - nipagin - nipazol (3:1) - 0.2, as base: carbopol gel 0.25% or CCMA 1% or Na-CMC 4% - remaining to 100.0.

EFFECT: expressed adsorbtion properties; convenient dozing and application.

9 ex, 1 tbl

FIELD: chemistry.

SUBSTANCE: invention relates to novel derivatives of bis-(4-alkylaminopiridinium-1)alkanes of formula (1) where X stands for lipophilic anion from the following group: triiodide I3, iodate IO3, perchlorate ClO4; Y stands for either linear or branched alkylene group, which contains 4 to 18 carbon atoms; R stands for either linear or branched alkyl, cycloalkyl or arylalkyl group, which contains 5 to 18 carbon atoms, to methods of preparation thereof and application thereof as antibacterial and antiviral substances.

EFFECT: new substances show useful biological properties.

10 cl, 6 ex

FIELD: chemistry.

SUBSTANCE: invention relates to the compound with the formula (1): where R1 is C1-C12 alkyl group, which can have the substitute, or C2-C12 alkenyl group, which can have the substitute represented with the C6-C14 aryl group, which can be substituted with the halogen atoms; each of R2 and R3 represent the hydrogen atom, alkyl group, hydroxyalkyl group, dihydroxyalkyl group, or R2 and R3 form with the adjacent nitrogen atoms the 5-membered, 6-membered, or 7-membered nitrogen-containing saturated heterocyclic group, which can be substituted with the alkyl group; (the dotted line means the possible double bind), or its salt, as well as to the pharmaceutical composition containing the said compound, and to its application as a pharmaceuticals and to the treatment method.

EFFECT: invented compound demonstrates inhibiting activity against the tumor necrosis factor production (TNF-α) and improved absorbability after oral administration.

16 cl, 1 tbl, 18 dwg, 1 ex

FIELD: chemistry.

SUBSTANCE: invention refers to new pyridazine -3 (2H) derivatives, the chemical formula of which corresponds to the general formula , in which R1, R2, R3, R4 and R5 have values indicated in the formula of the invention. The compounds of the formula (I) are effective and selective inhibitors of phosphodiesterase 4. The invention also refers to the method of their preparation, pharmaceutical composition which includes these compounds, and to the application for medicine preparation for treatment of disease state or disease which medicable by meance of phosphodiesterase 4 inhibition. Besides, the object of the invention is the method of disease state and disease treatment by means of phosphodiesterase 4 inhibition.

EFFECT: new compounds have effective biological properties.

19 cl, 25 tbl, 278 ex

FIELD: medicine; rheumatology.

SUBSTANCE: invention can be used for treatment of steroid-dependant rheumatoid arthritis. For this purpose basic and anti-inflammatory therapy is performed including agents of calcium and native vitamin D. Additionally agent of active vitamin D - alpha-calcydol is prescribed. At that agent dose from minimum (0.5 mcg) to maximum (1.5 mcg), therapy duration and multiplicity are prescribed on the basis of dose and duration of prescribed corticosteroids in terms of prednisolone.

EFFECT: invention enables to increase remission period due to individual optimal selection of therapy.

4 cl, 2 ex

FIELD: medicine; physiotherapy.

SUBSTANCE: patient is prescribed with balneo-, EHF-, pelotherapy within period from November to January, and in July. If patient is treated from February to June, and from August to October, treatment also includes phytotherapy. Phytotherapy includes application of leuzeae tincture and phytotea containing: pure licorice root - 1 portion, garden violet herb - 1 portion, rosehip - 2 portions, common birch leaves - 2 portions, lingonberry leaves - 2 portions, trifid beggars-ticks herb - 2 portions. leuzeae tincture is taken in dose 15-20 drops 30-40 minutes after eating, twice a day, within first half of day. Phytotea is taken in dose 40-50 ml 20-30 minutes before eating, 3 times a day.

EFFECT: reduces treatment time; increases treatment efficiency.

2 ex, 3 tbl

FIELD: medicine.

SUBSTANCE: invention refers to medicine and can be applied for treatment of dystrophic diseases of musculoskeletal system: deforming osteoarthrosis or osteohondrosis. Electrophoresis is applied with saline sediment of mineral water "Amurskaya-2" within 15 to 30 minutes, for 10-15 procedures. For deforming osteoarthrosis treatment current intensity is 20 - 30 mA, and for osteohondrosis treatment - 15-20 mA. Method ensures reduced treatment duration and improved quality of life for patients with musculoskeletal system diseases.

EFFECT: reduced treatment duration and improved quality of life for patients with musculoskeletal system diseases.

2 ex

FIELD: chemistry.

SUBSTANCE: invention relates to the formula I compounds or its pharmaceutically acceptable salt or hydrate where Z means N; X1 means O or S, R1 means alkyl containing one to six carbon atoms; R2 designates hydrogen or alkyl containing one to six carbon atoms; and R3 designates hydrogen or alkyl containing one to six carbon atoms substituted with the -ORa group where Ra means alkyl containing one to six carbon atoms; saturated nonaromatic cyclic radical containing 3 to 8 atoms in a cycle where one atom in a cycle is a heteroatom selected from N or O, whereas the rest of the atoms in the cycle are carbon atoms, one or two of these carbon atoms being not necessarily substituted by nitrogen atom with the groups -C(O)(C1-C6alcoxy) or -SO2-C1C6alkyl. Invention also relates to pharmaceutical composition.

EFFECT: compounds possess inhibiting activity.

13 cl, 1 tbl, 8 ex

FIELD: medicine; pharmacology.

SUBSTANCE: invention relates to the novel compounds with formula (I) and their pharmaceutically acceptable salts. The compounds of this invention has the properties of the NPY receptor antagonists and can be used fortreatment of such diseases as arthritis, diabetes, malnutrition, obesity. In general formula (I) , R1 means phenyl or 6-term nitrogen-containing heteroaryl, where in at least one of two meta-positions each phenyl group or 6-term nitrogen-containing heteroaryl group is substituted by group R5; R2 means hydrogen; R3 means C3-C6cycloalkyl, naphthyl, phenyl or 5-6-term heteroaryl, containing N or S as heteroatoms, where in at least one of two ortho-positions each group of C3-C6 cycloalkyl, naphthyl, phenyl or 5-6-term heteroaryl, containing N or S as heteroatoms, substituted by group R6; R4 means hydrogen, C1-C6alkyl; R5 means hydrogen, cyano, trifluoromethyl, C1-C6alkyl-SO2-, amino-SO2-, halogen, C1-C6alcoxy, C1-C6alkylcarbonil or aminocarbonil; R6 means hydrogen, halogen, cyano, nitro, trifluoromethyl, C1-C6 alkyl, C1-C6 alcoxy or hydroxy, provided, one R5 group, and R6 doesn't mean hydrogen.

EFFECT: described compounds and based on them pharmaceutical agents are efficient in treatment and prevention of above listed diseases.

19 cl, 2 tbl, 2 dwg, 130 ex

FIELD: medicine; pharmacology.

SUBSTANCE: invention relates to the method of treatment of diseases caused by abnormality of cartilaginous and/or bone tissue; the method includes the treatment course of applications of hydrolysed collagen and cosmetic clay to the painful area, when the KollAmin-80 or Epydermat-0 are rubbed into the painful area, and then the diluted cosmetic clay is applied, the area is covered with the polyethylene film or compressor paper and warmth-keeping for 30-40 min once daily, with course of 30-60 days 3-6 times annually.

EFFECT: high therapeutic efficiency is achieved.

2 cl, 9 ex

FIELD: medicine.

SUBSTANCE: preparation has mixture of collagen I and collagen II taken approximately in 1:19 to 19:1 proportion, respectively. The matrix is usable as supporting implant for restructuring cartilage of vertebral column or meniscus.

EFFECT: stimulated injured cartilage recovery.

19 cl, 2 dwg, 1 tbl

FIELD: medicine, pharmaceutical industry.

SUBSTANCE: invention represents a drug of the following composition, wt.-%: chondroitin sulfate, 1.0-10.0; sodium diclofenac, 1.0-10.0; dimethylsulfoxide, 5.0-25.0, and ointment base, the balance. Ointment base represents pentol, stearic acid, vaseline, lanolin and water, polymeric-base gel, or polyethylene oxides. Proposed drug possesses the combined effect.

EFFECT: improved and valuable medicinal properties of agent.

2 cl, 1 tbl, 3 ex

FIELD: medicine.

SUBSTANCE: invention concerns thrombocyte disturbance levelling for metabolic syndrome. For this purpose applied age and sex-specific hypo-calorie diet is calculated by formula combined with introduction of diazepam dosed 90 mg twice a day, methphormine 850 mg once a day in the evening and riboxyne 0.2 g 2 tablets 3 times a day.

EFFECT: widen range of means for effective correction of thrombocyte haemostasis associated with metabolic syndrome.

1 ex

Up!